Clinical trials
Phase 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| PETHEMA Foundation | 3 |
| Amgen Research (Munich) GmbH | 2 |
| Fundació Sant Joan de Déu | 1 |
| Goethe University | 1 |
| Grupo Espanol de trasplantes hematopoyeticos y terapia celular | 1 |
| Janssen Research & Development, LLC | 1 |
| Jazz Pharmaceuticals | 1 |
| MedImmune LLC | 1 |
| Pfizer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 18 |
| Leukemia | 5 |
| Burkitt Lymphoma | 3 |
| Leukemia, B-Cell | 2 |
| Leukemia, Lymphoid | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Lymphatic Diseases | 2 |
| Lymphoproliferative Disorders | 2 |
| Neoplasm, Residual | 2 |
| Neoplasms | 2 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.